Changshan Kaijiejian Biopharmaceutical Research and Development

Changshan Kaijiejian Biopharmaceutical Research and Development is a joint venture established by Hebei Changshan Biochemical Pharmaceutical and Conjupro Biotherapeutics, a subsidiary of Hanmi Pharmaceutical. The company focuses on the development and commercialization of innovative metabolic drugs in the Chinese market, most notably the long-acting GLP-1 receptor agonist efpeglenatide. Efpeglenatide utilizes Hanmi's LAPSCOVERY technology to extend the drug's half-life, allowing for less frequent dosing. The company is primarily dedicated to addressing the growing prevalence of type 2 diabetes and obesity in China. By combining Changshan's local manufacturing expertise with Hanmi's advanced drug delivery platform, the venture aims to bring next-generation biologics to Chinese patients.